WO2004078181A1 - Rna interference based methods and compositions for inhibiting hbv gene expression - Google Patents
Rna interference based methods and compositions for inhibiting hbv gene expression Download PDFInfo
- Publication number
- WO2004078181A1 WO2004078181A1 PCT/CN2003/000718 CN0300718W WO2004078181A1 WO 2004078181 A1 WO2004078181 A1 WO 2004078181A1 CN 0300718 W CN0300718 W CN 0300718W WO 2004078181 A1 WO2004078181 A1 WO 2004078181A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sequence
- seq
- dsrna
- cell
- hbv
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003258452A AU2003258452A1 (en) | 2003-03-05 | 2003-08-25 | Rna interference based methods and compositions for inhibiting hbv gene expression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN03119222.X | 2003-03-05 | ||
CNB03119222XA CN1257284C (en) | 2003-03-05 | 2003-03-05 | Method of blocking expression of hepatitis B virus |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004078181A1 true WO2004078181A1 (en) | 2004-09-16 |
Family
ID=32932360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2003/000718 WO2004078181A1 (en) | 2003-03-05 | 2003-08-25 | Rna interference based methods and compositions for inhibiting hbv gene expression |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR20060029597A (en) |
CN (1) | CN1257284C (en) |
AU (1) | AU2003258452A1 (en) |
WO (1) | WO2004078181A1 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006023491A2 (en) | 2004-08-16 | 2006-03-02 | The Cbr Institute For Biomedical Research, Inc. | Method of delivering rna interference and uses thereof |
WO2006096018A1 (en) * | 2005-03-09 | 2006-09-14 | Mogam Biotechnology Research Institute | Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same |
GB2439543A (en) * | 2006-06-27 | 2008-01-02 | Viruvation B V | Polyoma viral vector production cell lines and nucleic acids expressing dsRNA viral sequences |
CN100420749C (en) * | 2006-02-10 | 2008-09-24 | 南京吉脉生物技术有限公司 | Application of ShRNA pointed at HBV gene in inhibiting hepatitis B virus duplication |
CN101979558A (en) * | 2010-10-28 | 2011-02-23 | 百奥迈科生物技术有限公司 | Small interfering RNA (siRNA) molecule of targeted hepatitis B virus (HBV) gene and application thereof |
CN101979556A (en) * | 2010-10-28 | 2011-02-23 | 百奥迈科生物技术有限公司 | Small interfering ribose nucleic acid (siRNA) targeting molecule and application thereof |
EP2316942A1 (en) * | 2004-12-22 | 2011-05-04 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
WO2012045894A1 (en) * | 2010-10-05 | 2012-04-12 | Proyecto De Biomedicina Cima, S.L. | Compounds and compositions for the treatment of illnesses caused by the hepatitis b virus |
WO2012075337A2 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
EP2512491A1 (en) * | 2009-10-16 | 2012-10-24 | Glaxo Group Limited | Hbv antisense inhibitors |
US8350021B2 (en) | 2003-06-12 | 2013-01-08 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US9034841B2 (en) | 2011-04-21 | 2015-05-19 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis B virus (HBV) expression |
EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
WO2017190197A1 (en) * | 2016-05-05 | 2017-11-09 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
WO2019079781A3 (en) * | 2017-10-20 | 2019-05-23 | Dicerna Pharmaceuticals, Inc | Methods for treating hepatitis b infection |
EP3395363A4 (en) * | 2015-11-09 | 2019-08-28 | IDAC Theranostics, Inc. | Antiviral drug |
JP2019527694A (en) * | 2016-08-04 | 2019-10-03 | アローヘッド ファーマシューティカルズ インコーポレイテッド | RNAi drugs for hepatitis B virus infection |
US10513703B2 (en) | 2014-11-10 | 2019-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
JP2021503941A (en) * | 2017-12-01 | 2021-02-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | Nucleic acid, compositions and complexes containing the nucleic acid, and preparation methods and uses |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
RU2780021C2 (en) * | 2017-10-20 | 2022-09-19 | Дайсерна Фармасьютикалз, Инк | Methods for treatment of hepatitis b infection |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11534453B2 (en) | 2015-08-07 | 2022-12-27 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for hepatitis B virus infection |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1312283C (en) * | 2004-12-07 | 2007-04-25 | 浙江大学 | Smal linterference ribonucleic acid sequence of hepatitis B virus gene and preparing method |
WO2010012244A1 (en) * | 2008-08-01 | 2010-02-04 | 苏州瑞博生物技术有限公司 | Small rna interference target site sequences of hepatitis b virus and small interference rnas and the compositions and uses thereof |
CN101979553B (en) * | 2010-10-28 | 2015-07-01 | 百奥迈科生物技术有限公司 | siRNA molecule for interfering HBV gene and antiviral application thereof |
CN101979554B (en) * | 2010-10-28 | 2015-08-26 | 百奥迈科生物技术有限公司 | A kind of siRNA molecule and application thereof disturbing HBV gene |
CN102021170B (en) * | 2010-10-28 | 2015-07-01 | 百奥迈科生物技术有限公司 | Small interfering ribonucleic acid (siRNA) molecule of interfering hepatitis B virus gene and application thereof |
KR101879329B1 (en) | 2016-06-13 | 2018-07-17 | 충북대학교 산학협력단 | RNA-seq expression data simulation method for differential gene expression analysis, and recording medium thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006693A1 (en) * | 1990-10-22 | 1992-04-30 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
WO1999020641A1 (en) * | 1997-10-21 | 1999-04-29 | Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences | New triplex forming oligonucleotides and their use in anti-hbv |
WO2002083908A1 (en) * | 2001-03-30 | 2002-10-24 | Fundacion Para La Investigacion Medica Aplicada | Method for reversible inhibition of gene expression by modified ribonucleoproteins |
-
2003
- 2003-03-05 CN CNB03119222XA patent/CN1257284C/en not_active Expired - Fee Related
- 2003-08-25 KR KR1020057016557A patent/KR20060029597A/en not_active Application Discontinuation
- 2003-08-25 AU AU2003258452A patent/AU2003258452A1/en not_active Abandoned
- 2003-08-25 WO PCT/CN2003/000718 patent/WO2004078181A1/en not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006693A1 (en) * | 1990-10-22 | 1992-04-30 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
WO1999020641A1 (en) * | 1997-10-21 | 1999-04-29 | Shanghai Institute Of Biochemistry, Chinese Academy Of Sciences | New triplex forming oligonucleotides and their use in anti-hbv |
WO2002083908A1 (en) * | 2001-03-30 | 2002-10-24 | Fundacion Para La Investigacion Medica Aplicada | Method for reversible inhibition of gene expression by modified ribonucleoproteins |
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200281B2 (en) | 2003-06-12 | 2015-12-01 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US8350021B2 (en) | 2003-06-12 | 2013-01-08 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US9982263B2 (en) | 2003-06-12 | 2018-05-29 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
US10982212B2 (en) | 2003-06-12 | 2021-04-20 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
WO2006023491A2 (en) | 2004-08-16 | 2006-03-02 | The Cbr Institute For Biomedical Research, Inc. | Method of delivering rna interference and uses thereof |
EP2316942A1 (en) * | 2004-12-22 | 2011-05-04 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
WO2006096018A1 (en) * | 2005-03-09 | 2006-09-14 | Mogam Biotechnology Research Institute | Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same |
CN100420749C (en) * | 2006-02-10 | 2008-09-24 | 南京吉脉生物技术有限公司 | Application of ShRNA pointed at HBV gene in inhibiting hepatitis B virus duplication |
GB2439543A (en) * | 2006-06-27 | 2008-01-02 | Viruvation B V | Polyoma viral vector production cell lines and nucleic acids expressing dsRNA viral sequences |
EP2512491A1 (en) * | 2009-10-16 | 2012-10-24 | Glaxo Group Limited | Hbv antisense inhibitors |
US8598334B2 (en) | 2009-10-16 | 2013-12-03 | Glaxo Group Limited | HBV antisense inhibitors |
JP2013507933A (en) * | 2009-10-16 | 2013-03-07 | グラクソ グループ リミテッド | HBV antisense inhibitor |
EP2512491A4 (en) * | 2009-10-16 | 2013-04-24 | Glaxo Group Ltd | Hbv antisense inhibitors |
WO2012045894A1 (en) * | 2010-10-05 | 2012-04-12 | Proyecto De Biomedicina Cima, S.L. | Compounds and compositions for the treatment of illnesses caused by the hepatitis b virus |
CN101979556A (en) * | 2010-10-28 | 2011-02-23 | 百奥迈科生物技术有限公司 | Small interfering ribose nucleic acid (siRNA) targeting molecule and application thereof |
CN101979556B (en) * | 2010-10-28 | 2015-01-21 | 百奥迈科生物技术有限公司 | Small interfering ribose nucleic acid (siRNA) targeting molecule and application thereof |
CN101979558A (en) * | 2010-10-28 | 2011-02-23 | 百奥迈科生物技术有限公司 | Small interfering RNA (siRNA) molecule of targeted hepatitis B virus (HBV) gene and application thereof |
WO2012075337A2 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
US9034841B2 (en) | 2011-04-21 | 2015-05-19 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis B virus (HBV) expression |
US9127278B2 (en) | 2011-04-21 | 2015-09-08 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis B virus (HBV) expression |
US9677076B2 (en) | 2011-04-21 | 2017-06-13 | Ionis Pharmaceuticals, Inc. | Modulation of hepatitis B virus (HBV) expression |
EP2966170A1 (en) * | 2014-07-10 | 2016-01-13 | Heinrich-Pette-Institut Leibniz-Institut für experimentelle Virologie-Stiftung bürgerlichen Rechts - | HBV inactivation |
US10513703B2 (en) | 2014-11-10 | 2019-12-24 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US11060091B2 (en) | 2014-11-10 | 2021-07-13 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) iRNA compositions and methods of use thereof |
US11534453B2 (en) | 2015-08-07 | 2022-12-27 | Arrowhead Pharmaceuticals, Inc. | RNAi therapy for hepatitis B virus infection |
EP3395363A4 (en) * | 2015-11-09 | 2019-08-28 | IDAC Theranostics, Inc. | Antiviral drug |
US10709727B2 (en) | 2015-11-09 | 2020-07-14 | Idac Theranostics, Inc. | Antiviral drugs |
US11535851B2 (en) | 2016-05-05 | 2022-12-27 | Benitec IP Holdings Inc. | Reagents for treatment of hepatitis B virus (HBV) infection and use thereof |
WO2017190197A1 (en) * | 2016-05-05 | 2017-11-09 | Benitec Biopharma Limited | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof |
JP2019527694A (en) * | 2016-08-04 | 2019-10-03 | アローヘッド ファーマシューティカルズ インコーポレイテッド | RNAi drugs for hepatitis B virus infection |
JP7237816B2 (en) | 2016-08-04 | 2023-03-13 | アローヘッド ファーマシューティカルズ インコーポレイテッド | RNAi agents for hepatitis B virus infection |
US11590156B2 (en) | 2016-08-04 | 2023-02-28 | Arrowhead Pharmaceuticals, Inc. | RNAi agents for hepatitis B virus infection |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US11273173B2 (en) | 2017-10-20 | 2022-03-15 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis B infection |
US10799524B2 (en) | 2017-10-20 | 2020-10-13 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis B infection |
US11052105B2 (en) | 2017-10-20 | 2021-07-06 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis B infection |
WO2019079781A3 (en) * | 2017-10-20 | 2019-05-23 | Dicerna Pharmaceuticals, Inc | Methods for treating hepatitis b infection |
RU2780021C2 (en) * | 2017-10-20 | 2022-09-19 | Дайсерна Фармасьютикалз, Инк | Methods for treatment of hepatitis b infection |
US11052104B2 (en) | 2017-10-20 | 2021-07-06 | Dicerna Pharmaceuticals, Inc. | Methods for treating hepatitis B infection |
US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
US11414665B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
JP2021503941A (en) * | 2017-12-01 | 2021-02-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | Nucleic acid, compositions and complexes containing the nucleic acid, and preparation methods and uses |
EP3718572A4 (en) * | 2017-12-01 | 2021-09-08 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method and use |
JP7273417B2 (en) | 2017-12-01 | 2023-05-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | Nucleic acids, compositions and complexes containing such nucleic acids, and preparation methods and uses |
US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
US11492623B2 (en) | 2018-08-13 | 2022-11-08 | Alnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof |
US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20060029597A (en) | 2006-04-06 |
AU2003258452A8 (en) | 2004-09-28 |
CN1257284C (en) | 2006-05-24 |
CN1526818A (en) | 2004-09-08 |
AU2003258452A1 (en) | 2004-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004078181A1 (en) | Rna interference based methods and compositions for inhibiting hbv gene expression | |
US8513401B2 (en) | Double stranded nucleic acid targeting low copy promoter-specific RNA | |
JP5383186B2 (en) | Nucleic acid agents that down-regulate H19 and methods of using the same | |
JP4463554B2 (en) | In vitro synthesis method of short double-stranded RNA | |
US8486910B2 (en) | SnoRNAi-small nucleolar RNA degradation by RNA interference in trypanosomatids | |
KR20010099682A (en) | Enzymatic Synthesis of ssDNA | |
CA2675967A1 (en) | Nucleic acid constructs and methods for specific silencing of h19 | |
JP2011507554A (en) | Methods and compositions for increasing gene expression | |
US9222090B2 (en) | RNA interference target for treating AIDS | |
JP2007530431A (en) | Compositions and methods for treating pancreatic cancer | |
JP2020037599A (en) | Production and utilization of novel therapeutic anti-cancer agents | |
WO2017087828A1 (en) | Method to modulate smooth muscle cell differentiation | |
JP4467559B2 (en) | Compositions and methods for inhibiting cell proliferation | |
US20080207539A1 (en) | Self-Processing Rna Expression Cassette | |
Yuan et al. | Asymmetric siRNA: new strategy to improve specificity and reduce off-target gene expression | |
EP1849865B1 (en) | RNAi MEDICINE HAVING NO ADVERSE EFFECTS | |
Liu et al. | Short hairpin RNA and retroviral vector-mediated silencing of p53 in mammalian cells | |
US20110008885A1 (en) | Linear double-stranded rna molecule interfering with different target genes | |
JP2006180710A (en) | Rna inhibiting expression of klf5 gene | |
CN113227375A (en) | Synthetic microRNA mimetics | |
CN105803056B (en) | Application of human IARS2 gene and related medicine thereof | |
Morral et al. | shRNA-induced interferon-stimulated gene analysis | |
JP4505566B2 (en) | Lung cancer therapeutic agent | |
Wu et al. | Characterization of the swine U6 promoter for short hairpin RNA expression and its application to inhibition of virus replication | |
JP2011188849A (en) | miR-7 EXPRESSION PLASMID HAVING ANTITUMOR EFFECT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1-2005-501590 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057016557 Country of ref document: KR Ref document number: 1756/KOLNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200501430 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057016557 Country of ref document: KR |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |